Drug Trial Radar · NCT01986907
Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
Last checked: Nov 20, 2026Latest source record: Jul 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,049
Actual
Start
Mar 4, 2014
Primary completion
Jun 15, 2016
Study completion Jun 15, 2016
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of ranibizumab in patients affected by wet age related macular degeneration (wAMD).
Conditions
- Wet Age Related Macular Degeneration
Interventions
ranibizumabDrug
All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Systemic Drug-related Adverse EventsTime frame: Baseline to Month 12
- Number of Eyes With Ocular Drug-related Adverse EventsTime frame: Baseline to Month 12
Locations
101 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Borgomanero, Italy
Novartis Investigative Site
Galliate, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Pozzuoli, Italy
Novartis Investigative Site
Alessandria, AL, Italy
Novartis Investigative Site
Casale Monferrato, AL, Italy
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Acquaviva delle Fonti, BA, Italy
Novartis Investigative Site
Putignano, BA, Italy
Novartis Investigative Site
Terlizzi, BA, Italy
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Belluno, BL, Italy
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Desenzano del Garda, BS, Italy
Novartis Investigative Site
Bolzano, BZ, Italy
Novartis Investigative Site
Cagliari, CA, Italy
Novartis Investigative Site
Larino, CB, Italy
Novartis Investigative Site
Caserta, CE, Italy
Novartis Investigative Site
Chieti, CH, Italy
Novartis Investigative Site
Ceva, CN, Italy
Novartis Investigative Site
Cuneo, CN, Italy
Novartis Investigative Site
Como, CO, Italy
Novartis Investigative Site
San Feramo Della Battaglia, CO, Italy
Novartis Investigative Site
Acireale, CT, Italy
Novartis Investigative Site
Catania, CT, Italy
Novartis Investigative Site
Catania, CT, Italy
Novartis Investigative Site
Catanzaro, CZ, Italy
Novartis Investigative Site
Forlì, FC, Italy
Novartis Investigative Site
Cona, FE, Italy
Novartis Investigative Site
Foggia, FG, Italy
Novartis Investigative Site
San Giovanni Rotondo, FG, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Rapallo, GE, Italy
Novartis Investigative Site
Crotone, KR, Italy
Novartis Investigative Site
Tricase, LE, Italy
Novartis Investigative Site
Terracina, LT, Italy
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.